TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most ...

As antibiotic resistance grows, so does research toward preventing and treating Clostridioides difficile, a bacterium known to be one of the leading causes of healthcare-associated infections in U.S.

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

A new antibiotic to fight the deadly "superbug" C. diff has proved effective in clinical trials. Treating patients with ibezapolstat provided high rates of "sustained" clinical cures, say American ...

Newly discovered iron storage 'ferrosomes' inside the bacterium C. diff -- the leading cause of hospital-acquired infections -- are important for infection in an animal model and could offer new ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

When I took antibiotics for a sinus infection, I began feeling weak and feverish, with diarrhea. I went to the ER and learned I had Clostridioides difficile, an infection in the large intestine. The ...

The hospital-acquired infection Clostridium difficile, which causes inflammation of the colon and can be deadly among elderly patients, may be spread outside the hospital setting via food, according ...

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new ...

Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

Kevin Garey, University of Houston Robert L. Boblitt Endowed Professor of Drug Discovery at the UH College of Pharmacy, assessed the pharmacokinetics and gut microbiome effects of oral Omadacycline in ...